Antifungal susceptibility testing of yeasts: Uses and limitations

Drug Resistance Updates

Volumn 3, Issue 1, 2000, Pages 14-19

  Reyes, Guadalupe ^a   Ghannoum, Mahmoud A ^a,b  

^a CASE WESTERN RESERVE UNIVERSITY   (United States)

^b UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B LIPID COMPLEX; ANTIFUNGAL AGENT; FLUCONAZOLE; FLUCYTOSINE; ITRACONAZOLE; TERBINAFINE;

ANALYTIC METHOD; ANTIFUNGAL ACTIVITY; BLOOD CULTURE; DRUG EFFECT; DRUG SENSITIVITY; HUMAN; IN VITRO STUDY; MINIMUM INHIBITORY CONCENTRATION; MYCOLOGY; PRIORITY JOURNAL; REPRODUCIBILITY; SHORT SURVEY; STRAIN DIFFERENCE; YEAST;

EID: 0034144564     PISSN: 13687646     EISSN: None     Source Type: Journal    
DOI: 10.1054/drup.2000.0127     Document Type: Article

References (55)

1. Anaissie E. J., Bodey G. P., Rinaldi M. G. Emerging fungal pathogens. Eur J Clin Microbiol Infect Dis. 8:1989;323-330.
2. Banerjee S. N., Emori T. G., Culver D. H. Secular trends in nosocomial primary bloodstream infections in the United States, 1980-1989. Am J Med. 91 (Suppl 3B):1991;86S-89S.
3. Pfaller M. A., Wenzel R. The impact of changing epidemiology of fungal infections in the 1990's. Eur J Clin Microbiol Infect Dis. 11:1992;287-291.
4. Richardson M. D. Opportunistic and pathogenic fungi. J Antimicrob Chemother. 28 (Suppl A):1991;1-11.
5. Horsburgh C. R., Kirkpatrick C. H. Long-term therapy of chronic mucocutaneous candidiasis with ketoconazole: Experience with twenty-one patients. Am J Med. 74:1983;23-29.
6. Merz W. G. Candida lusitaniae: Frequency of recovery, colonization, infection, and amphotericin B resistance. J Clin Microbiol. 20:1984;1194-1195.
7. Stiller R. L., Bennett J. E., Scholer H. J., Wall M., Polak A., Stevens D. A. Susceptibility to 5-fluorocytosine and prevalence of serotype in 402 Candida albicans isolates from the United States. Antimicrob Agents Chemother. 22:1982;482-487.
8. Wingard J. R., Merz W. G., Rinaldi M. G., Johnson T. R., Karp J. E., Saral R. Increase in Candida krusei infection among patients with bone marrow transplantation and neutropenia treated prophylactically with fluconazole. N Engl J Med. 325:1991;1274-1277.
9. Ghannoum M. A. Future of antimycotic therapy. Dermatol Ther. 3:1997;107-111.
10. Espinel-Ingroff A., Kerkering T. M., Goldson P. R., Shadomy S. Comparison study of broth macrodilution and microdilution antifungal susceptibility tests. J Clin Microbiol. 29:1991;1089-1094.
11. Espinel-Ingroff A., Kish C. W., Kerkering T. M. Collaborative comparison of broth macrodilution and microdilution antifungal susceptibility tests. J Clin Microbiol. 30:1992;3138-3145.
12. Fromtling R. A., Galgiani J. N., Pfaller M. A. Multicenter evaluation of a macrobroth antifungal susceptibility test for yeasts. Antimicrob Agents Chemother. 37:1993;39-45.
13. Guinet R., Nerson D., DeClosets F. Collaborative evaluation in seven laboratories of a standardized micromethod for yeast susceptibility testing. J Clin Microbiol. 26:1988;2307-2312.
14. Pfaller M. A., Burmeister L., Bartlett M. S., Rinaldi M. G. Multicenter evaluation of four methods of yeast inoculum preparation. J Clin Microbiol. 26:1988;1437-1441.
15. Pfaller M. A., Rinaldi M. G., Galgiani J. N. Collaborative investigation of variables in susceptibility testing of yeasts. Antimicrob Agents Chemother. 34:1990;1648-1654.
16. Polak A., Ansorg R., Bartmann K. G, Multizenter-Studie zur Standardisierung der Empfindlichkeitsbestimmung von Pilzen gegen 5-Fluorocytosin und Amphotericin B. Mykosen. 30:1987;306-314.
17. Shawar R., Paetznick V., Witte Z., Ensign L. G., Anaissie E., LaRocco M. Collaborative investigation of broth microdilution and semisolid agar dilution for in vitro susceptibility testing ofCandida albicans. J Clin Microbiol. 30:1992;1976-1981.
18. Troke P. F. Fluconazole Susceptibility Testing Group. Abstr 32nd Interscience Conf Antimicrob Agents Chemother. 1992;American Society for Microbiology. Washington, DC. p. 1596.
19. Ghannoum M. A., Ibrahim A. S., Fu Y., Shafiq M. C., Edwards J. E., Criddle R. S. Susceptibility testing of Cryptococcus neoformans: a microdilution technique. J Clin Microbiol. 30:1992;2881-2886.
20. Rex J. H., Cooper C. R. Jr, Merz W. G., Galgiani J. N., Anaissie E. J. Detection of amphotericin B-resistant Candida isolates in a broth-based system. Antimicrob Agents Chemother. 39:1995;906-909.
21. Sanati H., Larsen R., Sheehan D., Ritchie J., Spelberg B., Ghannoum M. Penassay medium produces broad range of MICs of amphotericin B (Amph B) against clinical isolates of C. neoformans in a microdilution broth assay. Abstr 95th Annu Meet Am Soc Microbiol. 1995;abstr F103.
22. Approved standard. Document M27-A. 1997.
23. Colombo A. L., Barchiesi F., McGough D. A., Rinaldi M. G. Comparison of Etest and National Committee for Clinical Laboratory Standards broth macrodilution method for azole antifungal susceptibility testing. J Clin Microbiol. 33:1995;535-540.
24. Pfaller M. A., Barry A. L. Evaluation of a novel colorimetric broth microdilution method for antifungal susceptibility testing of yeast isolates. J Clin Microbiol. 32:1994;1992-1996.
25. Tiballi R. N., He X., Zarins L. T., Revankar S. G., Kauffman C. A. Use of a colorimetric system for yeast susceptibility testing. J Clin Microbiol. 33:1995;915-917.
26. Wanger A., Mills K., Rex J. H. Comparison of ETest and macrobroth dilution for antifungal susceptibility testing. Abstr 34th Intersci Conf Antimicrob Agents Chemother. 1994;D20.
27. Warnock D. W., Arthington-Skaggs B. A., Li R-K. Antifungal drug testing and resistance in Aspergillus. Drug Resist Updates. 2:199;326-334.
28. Hawser S. P., Norris H., Jessup C. J., Ghannoum M. A. Comparison of a 2,3-bis(2-methoxy-4-nitro-5-sulfophenyl)-5-[(phenylamino)carbonyl]-2 H -tetrazolium hydroxide (XTT) colorimetric method with the standardized National Committee for Clinical Laboratory Standards Method: testing clinical yeast isolates for susceptibility to antifungal agents. J Clin Microbiol. 36:1998;1450-1452.
29. Jessup C. J., Warner J., Isham N., Hasan I., Ghannoum M. A. Antifungal susceptibility testing of dermatophytes: establishing a medium for inducing conidial growth and evaluation of susceptibility of clinical isolates. J Clin Microbiol. 38:2000;341-344.
30. Norris H. A., Elewski B. E., Ghannoum M. A. Optimal growth conditions for determining the antifungal susceptibility of three species of dermatophytes using a microdilution method. J Amer Acad Dermatol. 40 (Suppl 6):1999;S9-S13.
31. Ghannoum M. A. Is antifungal susceptibility testing useful in guiding fluconazole therapy? Clin Infect Dis. 22:1996;161-165.
32. Ghannoum M. A., Rex J., Galgiani J. Susceptibility testing of fungi. Current status of correlation of in vitro data with clinical outcome. J Clin Microbiol. 34:1996;489-495.
33. Baily G. G., Perry F. M., Denning D. W., Mandal B. K. Fluconazole-resistant candidiasis in an HIV cohort. AIDS. 8:1994;787-792.
34. Barchiesi F., Hollis R. J., McGough D. A., Scalise G., Rinaldi M. G., Pfaller M. A. DNA subtypes and fluconazole susceptibilities of Candida albicans isolates from the oral cavities of patients with AIDS. Clin Infect Dis. 20:1995;634-640.
35. Bart-Delabesse E., Boiron P., Carlotti A., Dupont B. Candida albicans genotyping in studies with patients with AIDS developing resistance to fluconazole. J Clin Microbiol. 31:1993;2933-2937.
36. Boken D. J., Swindells S., Rinaldi M. G. Fluconazole-resistant Candida albicans. Clin Infect Dis. 17:1993;1018-1021.
37. Dupont B., Improvisi L., Eliaszewicz M., Pialoux G. Resistance of Candida albicans to fluconazole in AIDS patients. Abstr 32nd Intersci Conf Antimicrob Agents Chemother. 1992;American Society for Microbiology. Washington, DC.
38. Heinic G. S., Stevens D. A., Greenspan D. Fluconazole-resistant Candida in AIDS patients. Report of two cases. Oral Surg Oral Med Oral Pathol. 76:1993;711-715.
39. Newman S. L., Flanigan T. P., Fisher A., Rinaldi M. G., Stein M., Vigilante K. Clinically significant mucosal candidiasis resistant to fluconazole treatment in patients with AIDS. Clin Infect Dis. 19:1994;684-686.
40. Pfaller M. A., Rhine-Chalberg J., Redding S. W. Variations in fluconazole susceptibility and electrophoretic karyotype among oral isolates of Candida albicans from patients with AIDS and oral candidiasis. J Clin Microbiol. 32:1994;59-64.
41. Redding S., Smith J., Farinacci G. Resistance of Candida albicans to fluconazole during treatment of oropharyngeal candidiasis in patients with AIDS: Documentation of in vitro susceptibility testing and DNA subtype analysis. Clin Infect Dis. 18:1994;240-242.
42. Reynes J., Malli M., Andr D., Janbon F., Bastide J. M. Traitement et prophylaxie secondaire par fluconazole des candidoses oropharyng es des sujets VIH+. Analyse mycologique des checs. Path Biol. 40:1992;513-517.
43. Sandven P., Bjorneklett A., Maeland A. Susceptibility testing of Norwegian Candida albicans strains to fluconazole: emergence of resistance. Antimicrob Agents Chemother. 37:1993;2443-2448.
44. Sangeorzan J. A., Bradley S. F., He X. Epidemiology of oral candidiasis in HIV infected patients: Colonization, infection, treatment, and emergence of fluconazole resistance. Am J Med. 97:1994;339-346.
45. Troillet N., Durussel C., Bille J., Glauser M. P., Chave J. P. Correlation between in vitro susceptibility of Candida albicans and fluconazole-resistant oropharyngeal candidiasis in HIV-infected patients. Eur J Clin Microbiol Infect Dis. 12:1993;911-915.
46. Rex J. H., Pfaller M., Galgiani J. Development of interpretive breakpoints for susceptibility testing: conceptual framework and analysis of in vitro-in vivo correlation data for fluconazole, itraconazole, and Candida infections. Clin Infect Dis. 24:1997;235-247.
47. Rex J. H., Pfaller M. A., Barry A. L., Nelson P. W., Webb C. D. Antifungal susceptibility testing of isolates from a randomized, multicenter trial of fluconazole vs. amphotericin B as treatment of non-neutropenic patients with candidemia. Antimicrob Agents Chemother. 39:1995;40-44.
48. Ganger G., Just-Nubling G., Eichel M., Hoika R., Stille W., Goethe J. Itraconazole solution in patients with non-response to fluconazole. Abstr 9th Int Conf on AIDS City Society. 1993.
49. Ng T., Denning D. W. Fluconazole resistance in Candida in patients with AIDS - a therapeutic approach. J Infect. 26:1993;117-125.
50. Rex J., Walsh T., Sobel J., Filler S., Pappas P., Dismukes W., Edwards J. Treatment guidelines for candidiasis. Clin Infect Dis. 2000.
51. Odds F. C. Should resistance to azole antifungals in vitro be interpreted as predicting clinical non-response? Drug Resist Updates. 1:1998;11-15.
52. Witt M., Lewis R., Larsen R. Identification of patients with acute AIDS-associated cryptococcal meningitis suitable for fluconazole therapy: the role of antifungal susceptibility testing. Clin Infect Dis. 22:1996;322-328.
53. Larsen, R. A. Bozzette, S. A. Jones, B. E. Haghighat, D. Leal, M. A. Fluconazole combined with flucytosine for cryptoccocal meningitis in persons with AIDS. Clin Infect Dis (in press).
54. Milechike E., Leal M., Haubrich R., See R., Bozzette S., Larsen R. High dose fluconazole with and without flucytosine for AIDS associated cryptococcal meningitis. Abstr IX Int Conf on AIDS/IV STD World Congr (Berlin). 1993;Wellcome Foundation. London.
55. Collin B., Clancy C. J., Nguyen M. H. Antifungal resistance in non- albicans Candida species. Drug Resist Updates. 2:1999;9-14.